A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway

Peking University

Status and phase: Unknown; Phase 4

Conditions: Diagnosis and Treatment of Depression

Treatments: Drug: risperidone; Drug: bupropion; Drug: aripiprazole

Study type: Interventional

Funder types: Other

Identifiers

NCT03148509

Z171100000117016

Details and patient eligibility

About

This study will recruit depressed patients unresponsive to selective serotonin reuptake inhibitor antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls. The subjects need to complete the brain positron emission tomography/magnetic resonance examination, stress assessment, genetic testing, clinical evaluation and neuropsychological tests. Using the data, this study aimed to identify the abnormalities of reward circuit of depression and its differences with other diseases, and its abnormalities in first-degree relatives of depression. The depressed patients who were ineffective in treatment with selective serotonin reuptake inhibitor antidepressants were then given combined medication with dopamine receptor-mediated drugs, including dopamine transporter inhibitor - bupropion, D2 receptor antagonist - risperidone, or D2 receptor partial agonist - aripiprazole, to examine the regulation of dopamine pathway and its relationship with the therapeutic effect. Through the above work, we will provide new evidence for integrating the biological evidence of dopamine reward pathway into the clinical practice of depression.

Enrollment: 300 estimated patients

Sex: All

Ages: 15 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients unresponsive to SSRI antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls

Exclusion criteria

• Major physical illness; other DSM-IV axis I mental illness; personality disorder, mental retardation; drug and/or alcohol dependence; pregnant or lactating women; MRI examination contraindications.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

300 participants in 3 patient groups

bupropion

Experimental group

Description:

receive bupropion

Treatment:

Drug: risperidone

risperidone

Experimental group

Description:

receive risperidone

Treatment:

Drug: aripiprazole

aripiprazole

Experimental group

Description:

receive aripiprazole

Treatment:

Drug: bupropion